JP2019524834A - ビグアナイド系による発達障害の治療方法 - Google Patents

ビグアナイド系による発達障害の治療方法 Download PDF

Info

Publication number
JP2019524834A
JP2019524834A JP2019508879A JP2019508879A JP2019524834A JP 2019524834 A JP2019524834 A JP 2019524834A JP 2019508879 A JP2019508879 A JP 2019508879A JP 2019508879 A JP2019508879 A JP 2019508879A JP 2019524834 A JP2019524834 A JP 2019524834A
Authority
JP
Japan
Prior art keywords
syndrome
metformin
patient
disorder
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019508879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524834A5 (enExample
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2019524834A publication Critical patent/JP2019524834A/ja
Publication of JP2019524834A5 publication Critical patent/JP2019524834A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019508879A 2016-08-18 2017-08-18 ビグアナイド系による発達障害の治療方法 Pending JP2019524834A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376488P 2016-08-18 2016-08-18
US62/376,488 2016-08-18
PCT/US2017/047505 WO2018035408A1 (en) 2016-08-18 2017-08-18 Methods of treating developmental disorders with biguanides

Publications (2)

Publication Number Publication Date
JP2019524834A true JP2019524834A (ja) 2019-09-05
JP2019524834A5 JP2019524834A5 (enExample) 2020-09-24

Family

ID=61190982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508879A Pending JP2019524834A (ja) 2016-08-18 2017-08-18 ビグアナイド系による発達障害の治療方法

Country Status (9)

Country Link
US (2) US10123979B2 (enExample)
EP (1) EP3484452A4 (enExample)
JP (1) JP2019524834A (enExample)
KR (1) KR20190039974A (enExample)
CN (1) CN109715144A (enExample)
AU (1) AU2017313823A1 (enExample)
CA (1) CA3033967A1 (enExample)
MX (1) MX2019001937A (enExample)
WO (1) WO2018035408A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970884A4 (en) 2013-03-14 2016-11-02 Univ Florida DI-AMINO ACID-REINFORCED PROTEINS ASSOCIATED WITH ALS
WO2016196324A1 (en) 2015-05-29 2016-12-08 University Of Floridia Research Foundation, Inc. Methods for diagnosing huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides
JP7526455B2 (ja) 2017-04-17 2024-08-01 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
JP7620988B2 (ja) 2019-09-20 2025-01-24 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出
GB202008699D0 (en) * 2020-06-09 2020-07-22 Healx Ltd Treatment
CN113318111A (zh) * 2021-06-21 2021-08-31 浙江大学 Nav1.1激动剂在制备治疗自闭症的药物中的应用
EP4440560A1 (en) * 2021-12-01 2024-10-09 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2012081713A1 (ja) * 2010-12-13 2012-06-21 学校法人福岡大学 血液脳関門障害症候群治療薬
WO2014210389A1 (en) * 2013-06-26 2014-12-31 Rett Syndrome Research Trust Rett syndrome and treatments therefore

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US8252321B2 (en) * 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
CN102058888B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种治疗能量代谢异常的药物组合物和其应用
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2012081713A1 (ja) * 2010-12-13 2012-06-21 学校法人福岡大学 血液脳関門障害症候群治療薬
WO2014210389A1 (en) * 2013-06-26 2014-12-31 Rett Syndrome Research Trust Rett syndrome and treatments therefore

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 448, JPN6021015280, 2014, pages 414 - 417, ISSN: 0004631234 *
JOURNAL OF PEDIATRIC ENDOCRINOLOGY AND METABOLISM, vol. 27, JPN7021001390, 2014, pages 23 - 29, ISSN: 0004631235 *
JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. Vol.333, supplement 1, JPN6021015279, 2013, pages 44 - 2292, ISSN: 0004631233 *
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, vol. 91, JPN7021001391, 1998, pages 598, ISSN: 0004631236 *
MOLECULAR PSYCHIATRY, vol. 22, JPN6021015278, 2017, pages 1140 - 1148, ISSN: 0004631232 *

Also Published As

Publication number Publication date
US20190046480A1 (en) 2019-02-14
KR20190039974A (ko) 2019-04-16
US10426746B2 (en) 2019-10-01
CN109715144A (zh) 2019-05-03
EP3484452A4 (en) 2020-04-01
CA3033967A1 (en) 2018-02-22
AU2017313823A1 (en) 2019-02-28
EP3484452A1 (en) 2019-05-22
MX2019001937A (es) 2019-10-02
US20180050001A1 (en) 2018-02-22
WO2018035408A1 (en) 2018-02-22
US10123979B2 (en) 2018-11-13

Similar Documents

Publication Publication Date Title
US10426746B2 (en) Methods of treating developmental disorders with biguanides
US12465597B2 (en) Methods of treating developmental disorders with gaboxadol
US20190328719A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211102